Cargando…

First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis

BACKGROUND: Currently, in Belgium, bevacizumab is reimbursed for ovarian cancer patients, based on a contract between the Minister and the manufacturer including confidential agreements. This reimbursement will be re-evaluated in 2018. OBJECTIVE: To support the reimbursement reassessment by calculat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neyt, Mattias, Vlayen, Joan, Devriese, Stephan, Camberlin, Cécile
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891000/ https://www.ncbi.nlm.nih.gov/pubmed/29630612 http://dx.doi.org/10.1371/journal.pone.0195134

Ejemplares similares

Cost-effectiveness of cardiac resynchronisation therapy for patients with moderate-to-severe heart failure: a lifetime Markov model
por: Neyt, Mattias, et al.
Publicado: (2011)

Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions
por: Neyt, Mattias, et al.
Publicado: (2010)

A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population
por: Neyt, Mattias, et al.
Publicado: (2012)

The cost-utility of catheter ablation of atrial fibrillation: a systematic review and critical appraisal of economic evaluations
por: Neyt, Mattias, et al.
Publicado: (2013)

Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
por: Marchetti, Claudia, et al.
Publicado: (2019)

Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
por: Nakai, Hidekatsu, et al.
Publicado: (2023)

Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis
por: Neyt, Mattias, et al.
Publicado: (2014)

Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial
por: Petracci, Elisabetta, et al.
Publicado: (2020)

Prolonged Cough in Pediatric Population First Line Care, Belgian Guidelines
por: Leconte, Sophie, et al.
Publicado: (2017)

An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals
por: Huylebrouck, M., et al.
Publicado: (2012)

By Belgians for Belgians
por: Childers, M. A.
Publicado: (1915)

Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort
por: Conic, Irena, et al.
Publicado: (2022)

Design of a medical record review study on the incidence and preventability of adverse events requiring a higher level of care in Belgian hospitals
por: Vlayen, Annemie, et al.
Publicado: (2012)

First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Chiang, Chi-Leung, et al.
Publicado: (2021)

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
por: Ricci, Francesca, et al.
Publicado: (2017)

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study(†)
por: Iwamoto, S., et al.
Publicado: (2015)

Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
por: Tate, Shinichi, et al.
Publicado: (2021)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
por: Su, Dan, et al.
Publicado: (2021)

Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
por: Liu, Jia, et al.
Publicado: (2022)

Cost–Utility of First-Line Actinic Keratosis Treatments in Finland
por: Soini, Erkki J., et al.
Publicado: (2015)

Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis
por: Hou, Yanli, et al.
Publicado: (2020)

Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer
por: Vlayen, Joan, et al.
Publicado: (2015)

Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis
por: Meijerink, Martijn R., et al.
Publicado: (2018)

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients
por: Berton, Dominique, et al.
Publicado: (2021)

First line targeted therapies in breast cancer: focus on bevacizumab
por: Milano, Amalia, et al.
Publicado: (2007)

Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
por: Liu, Jia, et al.
Publicado: (2022)

Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study
por: Daneels, Willem, et al.
Publicado: (2022)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Peng, Ye, et al.
Publicado: (2022)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
por: Zhou, Ting, et al.
Publicado: (2022)

Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma
por: Tseng, Chien-Yu, et al.
Publicado: (2023)

One Fourth of Unplanned Transfers to a Higher Level of Care Are Associated With a Highly Preventable Adverse Event: A Patient Record Review in Six Belgian Hospitals
por: Marquet, Kristel, et al.
Publicado: (2015)

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France
por: Gaugain, Loïg, et al.
Publicado: (2023)

Similarities and differences in the associations between patient safety culture dimensions and self-reported outcomes in two different cultural settings: a national cross-sectional study in Palestinian and Belgian hospitals
por: Najjar, Shahenaz, et al.
Publicado: (2018)

First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer
por: Roy, Somnath, et al.
Publicado: (2022)

Bevacizumab in the treatment of ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2011)

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
por: Kaseb, Ahmed O, et al.
Publicado: (2016)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
por: Alsaedi, Nasser G, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_npfabdrhi607mifgg4kodphpvt